Purdue Pharma Proposes New Chapter 11 Plan Amid Ongoing Bankruptcy Negotiations

Purdue Pharma, the controversial pharmaceutical company known for its role in the opioid crisis, has submitted a revised Chapter 11 reorganization plan as part of its bankruptcy proceedings. This significant move comes as the company seeks to navigate the challenging waters of its financial and ethical responsibilities stemming from its past practices related to the sale of OxyContin. The new proposal aims to satisfy numerous stakeholders in a complex legal landscape marked by extensive claims from various states, municipalities, and individuals affected by opioid addiction.

Continue reading